| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | | | | Searchterm 'Enhancement' was also found in the following services: | | | | |
| | |
| |
|
Drug Information and Specification
T1, Predominantly positive enhancement
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
OSMOLALITY
557 and 1603 mosm/kgH2O
PREPARATION
Finished product
INDICATION
Central nervous system / whole body
DEVELOPMENT STAGE
For sale / submit for approval
PRESENTATION
Vials of 15, 30 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
USA
Gadovist®
Submit for approval
Australia
Gadovist®
for sale
| | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Short name: Gd-EOB-DTPA, generic name: Gadoxetic acid, chemical compound: Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
Primovistâ„¢ (formerly Eovist®) is a nonionic water-soluble liver tissue-specific MRI contrast agent with positive enhancement. The agent allows detection and differentiation of hepatic tumors due to specific uptake by healthy liver tissue, but not by tumors in the affected organ. Gd-EOB-DTPA has hepatocyte-specific properties, but provides earlier perfusion information acquired within first ten minutes. Hepatocyte uptake generally occurs beyond 10 minutes. | | | | • View the DATABASE results for 'Gadoxetic Acid' (6).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
| | | | | | • View the DATABASE results for 'Half Fourier Acquisition Single Shot Turbo Spin Echo' (5).
| | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'Enhancement' was also found in the following services: | | | | |
| | |
| |
|
| | | | | | | | | • View the NEWS results for 'Heart MRI' (18).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Perflubron® is a perfluorochemical for use as an oral contrast agent. Due to its insolubility in water it does not mix with intestinal secretions; thus bowel lumina appear homogeneously dark on MR images when Perflubron® replaces bowel contents. Filled bowel loops appear black with all pulse sequences because the contrast agent lacks mobile protons.
It is commercially available as Imagent GI. Because rapid transit through the gastrointestinal tract it reaches the rectum within 30 to 40 minutes in most patients. MR imaging of the upper abdominal region should begin within 15 minutes and of the pelvic region 15 to 60 minutes after ingestion of perflubron.
See also Classifications, Characteristics, etc.
Drug Information and Specification
NAME OF COMPOUND
Perfluoroctylbromide
PHARMACOKINETIC
Gastrointestinal
CONCENTRATION
Water immiscible liquid
DOSAGE
9 mL per kg of body weight
PREPARATION
Finished product
DEVELOPMENT STAGE
For sale
PRESENTATION
Bottle of 200cc
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
USA
Imagent GI®
For sale
| | | | • View the DATABASE results for 'Imagent GI' (3).
| | | | Further Reading: | News & More:
|
|
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |